Application of tamoxifen, rapamycin and ginsenoside Rg3 composition in preparing medicaments for treating liver cancer

A technology of tamoxifen and ginsenosides, which is applied in the directions of drug combination, antitumor drug, pharmaceutical formula, etc.

Inactive Publication Date: 2012-08-08
JIANGSU PROVINCE HOSPITAL
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006]Current literature reports generally use tamoxifen or the combination of tamoxifen and rapamycin in clinical application, but actual clinical experience shows that patients are using the above-mentioned However, it is still found that the curative effect is not very synergistic, especially for patients with surgically resected liver cancer, the recurrence rate is high, and the postoperative healing is slow

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tamoxifen, rapamycin and ginsenoside Rg3 composition in preparing medicaments for treating liver cancer
  • Application of tamoxifen, rapamycin and ginsenoside Rg3 composition in preparing medicaments for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] 1. Reagents: RPMI-1640 medium was produced by GIBCOL BRL, USA; mouse anti-survivin, p70s6k Thr389 monoclonal antibody was purchased from Cell Signal; secondary antibody HRP-labeled anti-mouse lgG, chemiluminescence (ECL) substrate was purchased from Santa Cruz Company; Tamoxifen, rapamycin, and ginsenoside Rg3 were purchased from Sigma, Renilla luciferase plasmid pRL-CMV was purchased from Promega. The plasmid pLUC encoding the firefly luciferase gene and survivin promoter sequence was kindly given by Dr. Xun from the University of North Carolina.

[0020] 2. Cell culture: Human liver cancer HepG2 cell line is routinely cultured in RPMI-1640 culture medium, with 10% calf serum, human penicillin (concentration 100 U / ml) and streptomycin (concentration 100 μg / ml), 37 ℃、5%CO 2 Cultivate in an incubator. After 3 to 4 generations of adherent growth in the incubator, cells in the logarithmic growth phase were used for experiments.

[0021] 3. Grouping: The logarithmic growth ph...

Embodiment 2

[0033] Tamoxifen has achieved significant effects in inhibiting tumor growth in breast and liver cancer experiments. Tamoxifen combined with rapamycin and ginsenoside Rg3 can enhance the effect of its cytotoxic drugs. Therefore, the combination therapy of tamoxifen, rapamycin and ginsenoside Rg3 will provide an efficient, low-toxic and inexpensive method for the treatment of liver cancer.

[0034] We have carried out clinical testing for the expression of survivin, p-Akt, and ER in tissue specimens after liver cancer surgery. Part of the patients with positive expression of survivin and p-Akt have been partially treated with moxifen combined with rapamycin and ginsenoside during outpatient follow-up. Rg3, tamoxifen monotherapy and controlled observation follow-up, at least 2 courses of treatment. The results showed that: compared with the single-drug treatment group and the observation group (not administered in the control group), the three-drug combination treatment group (moxi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of tamoxifen combined with rapamycin and ginsenoside Rg3 in preparing medicaments for treating liver cancer. When the tamoxifen is combined with the rapamycin and the ginsenoside Rg3 to treat the liver cancer, sensibility of liver cancer cells on chemotherapy can be improved. The tamoxifen inhibits activeness of an Akt to induce apoptosis of mammary epithelialcells. When an Akt access is activated, breast cancer cells are induced to generate drug resistance to the tamoxifen. The tamoxifen, the rapamycin and the ginsenoside can be used jointly to induce the apoptosis of tumor cells in a cooperation mode. Besides, the ginsenoside Rg3 can inhibit expression of vascular endothelial growth factors (VEGF) of the tumor cells to inhibit the formation of tumorvessels, further can inhibit expression of matrix metalloproteinases and interfere interaction of endothelial cells and extracellular matrixes to block infiltration and metastasis of tumors, improve thoroughness of operation treatment and reduce the rate of recrudescence and metastasis after an operation, and can improve self immunity of a tumor patient, inhibit tumor metastasis and reduce toxic and side effects of the tumor patient after the chemoradiotherapy.

Description

technical field [0001] The invention relates to the application of tamoxifen combined with rapamycin and ginsenoside Rg3 in the preparation of drugs for treating liver cancer. Background technique [0002] Liver cancer is a high-incidence tumor in Jiangsu Province, with rapid progression and high morbidity and mortality. Except for the 5-year survival rate of patients with resectable small liver cancer reaching 80-90%, the average survival time of patients with inoperable liver cancer from the onset of symptoms is only 3-4 months. At present, surgical resection is still the main treatment for liver cancer. However, less than 10% of the total number of liver cancer patients can undergo complete liver cancer resection. The remaining 90% of liver cancer patients cannot be surgically removed, or even if surgical resection of liver cancer is possible, 80% of the patients recurrence within two years of surgery. [0003] Many clinicopathological factors affect the prognosis of li...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00A61K31/436A61K31/138
Inventor 郭人花金时代陈小锋朱蔚友束永前王同杉
Owner JIANGSU PROVINCE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap